The Dayton School Department says it will roll out a fully electric school bus fleet this month thanks to a $1.5 million federal grant. The York County school district announced Tuesday that it took ...
Eli Lilly should become a much bigger money machine with multiple growth drivers in its product lineup and a promising ...
With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...
This Short discusses the potential growth of a $100 investment over time, using three examples. Investing $100 in Eli Lilly ...
The Golden Globes have a reputation for being Hollywood’s least serious awards show, allowing us all to revel in the mess.
Amazon.com’s Prime Video streaming service has licensed what it said was a documentary about former and future first lady ...
It’s ordinary people, and not superheroes, who bring about justice and change in the real world. In “Lilly,” writer-director ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...
Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...
Just to put into perspective how big a tailwind that weight loss space is for these companies, consider that Lilly's market value is larger than Pfizer's, Moderna's, and J&J's combined!
Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...